An Investigator Initiated Prospective, Four Arms Randomized Comparative Study of Efficacy and Safety of Saroglitazar, Vitamin E and Life Style Modification in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)/ Non-alcoholic Steatohepatitis (NASH)
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 250
- 试验地点
- 1
- 主要终点
- Change in Non alcoholic fatty liver fibrosis score at 8week, 16week and 24week.
研究概览
简要总结
Saroglitazar and Vitamin E are both being extensively used in India for non alcoholic fatty liver disease, though none of these drugs are FDA approved for this indication.However they are backed up by number of studies which shows improvement in liver function , reduction in NAS score. However, there is no head to head trial , nor is there any study with a paired biopsy comparing two arms for a head to head study. We therefore designed this study to see the effect of Vitamin E vs Vitamin E plus saroglitazar vs Saroglitazar alone when compared to standard dietary and weight loss treatment for NAFLD with raised ALT levels.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults (age 18 to 60)
- •Confirmed Diagnosis of NAFLD established either by imaging (ultrasound, CT scan or MRI) or liver biopsy showing simple steatosis, within 6 months of the Screening Phase for this study. The diagnosis of NAFLD is made according to the American Association for the Study of Liver Diseases (AASLD) criteria (Chalasaniet al.2017).
- •There is hepatic steatosis by imaging or histology,
- •There is no significant alcohol consumption,
- •There are no competing etiologies for hepatic steatosis
- •There are no co-existing causes for chronic liver disease.
- •Patient's demonstration of understanding of study requirements and treatment procedures, willingness to comply with all protocol-required evaluations.
- •Either take biopsy proven NAFLD or imaging based NAFLD with ALT more than 1.5 times the upper limit of normal. (being considered as 32)
- •Liver biopsy would be done in selected cases where the cause of transaminitis was uncertain of possible biopsy would be done on case to case basis.
排除标准
- •Absence of regular or excessive use of alcohol within 2 years prior to initial screening. History of alcohol will be taken from the patient and one or more family member and patient will be defined as non-alcoholic if he/she is a total abstainer or takes >20g (males) or 10g (females) of alcohol per day or greater than 14 drinks per week in males or greater than 7 drinks per week in females. Approximately 10 g of alcohol equals one 'drink' unit. One unit equals 30 ml of distilled spirits, 355 ml beer, or 120 ml glass of wine.
- •Presence of alternative causes of fatty liver, including:
- •Weight loss >10% in the 6 months before the Screening Visit
- •Total parenteral nutrition, starvation or protein-calorie malnutrition
- •Use of drugs associated with NAFLD for more than 12 consecutive weeks in the 1 year before start of the study, including amiodarone, tamoxifen, methotrexate, systemic glucocorticoids, anabolic steroids, tetracycline, estrogens in doses higher than used in oral contraceptives, vitamin A, L asparaginase, valproate, chloroquine, or antiretroviral drugs.
- •History of bowel surgery, gastrointestinal (bariatric) surgery or undergoing evaluation for bariatric surgery for obesity, extensive small-bowel resection, or orthotopic liver transplants (OLT) or listed for OLT.
- •History of other chronic liver disease (Viral hepatitis B or C, autoimmune hepatitis, cholestatic and metabolic liver diseases) and hemochromatosis.
- •Patient has known cirrhosis (compensated /decompensated) either based on clinical criteria or liver histology or Imaging techniques.
- •Patients with Hypothyroidism.
- •Unstable cardiovascular disease, including:
- •unstable angina, (i.e., new or worsening symptoms of coronary heart disease within the past 3 months), acute coronary syndrome within the past 6 months, acute myocardial infarction in the past 3 months or heart failure of New York Heart Association class (III - IV) or worsening congestive heart failure, or coronary artery intervention, within the past 6 months
- •history of (within prior 3 months) or current unstable cardiac dysarrhythmias
- •uncontrolled hypertension (systolic BP>180 mmHg and/or diastolic BP >110 mmHg on two consecutive occasions)
- •stroke or transient ischemic attack within the prior 6 months
- •History of myopathies or evidence of active muscle disease.
- •History of malignancy in the past 5 years and/or active neoplasm with the exception of resolved superficial non-melanoma skin cancer.
- •Participation in any other therapeutic clinical study in the past 3 months, including participation in any other NAFLD clinical trials.
- •History of bladder disease and/or hematuria or has current hematuria except due to a urinary tract infection.
- •Illicit substance abuse within the past 12 months.
- •Pregnant/lactating female (including positive pregnancy test at the Screening Visit)
- •History or other evidence of severe illness or any other conditions that would make the patient, in the opinion of the investigator, unsuitable for the study (such as poorly controlled psychiatric disease, HIV, coronary artery disease or active gastrointestinal conditions that might interfere with drug absorption).
- •Patients who will not comply with diet and lifestyle changes can be excluded from the final analysis.
研究组 & 干预措施
Saraglitazar
Patients will receive Saraglitazar 4 mg once daily for 6 months
干预措施: Saroglitazar (Drug)
Vitamin E
Patients will receive Vitamin E 400mg twice daily for 6 months
干预措施: Vitamin E (Drug)
Combination
Patients will receive combination of Saraglitazar 4 mg once daily and Vitamin E 400mg twice daily for 6 months
干预措施: Combination drug (Drug)
Lifestyle
Patients will follow instruction from dietician and life style changes advise as per protocol including targeting 7 to 10percent weight loss in 6 months
干预措施: Lifestyle Changes (Behavioral)
结局指标
主要结局
Change in Non alcoholic fatty liver fibrosis score at 8week, 16week and 24week.
时间窗: 6 months
Non alcoholic fatty liver fibrosis score would be assessed . This is a non invasive test calculated by the formula : -1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m2) + 1.13 × IFG/diabetes (yes = 1, no = 0) + 0.99 × AST/ALT ratio - 0.013 × platelet (×109/l) - 0.66 × albumin (g/dl) Results are interpreted as : NAFLD Score \< -1.455 = F0-F2 NAFLD Score -1.455 - 0.675 = indeterminate score NAFLD Score \> 0.675 = F3-F4 Change in the NAFLD fibrosis score from the initiation of treatment and at end of 6 months would be assessed.
次要结局
- Change in fibrosis on Liver Biopsy at 6 months.(6 months)
- Serum Alanine aminotransferase (ALT) changes at 6 months.(6 months)
- Serum Aspartate aminotransferase (AST) level at 6 months.(6 months)
- Non alcoholic steatosis (NAS) score on liver biopsy at 6 months.(6 months)
- Serum triglycerides (TG) level.(6 months)
- Glycosylated Hemoglobin (HbA1C) Level at 6 months.(6 months)